Compare Novartis AG (NVS) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Oxford Lane Capital Corp — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Oxford Lane Capital Corp trades at $8.62 (market cap $829.34M). The key difference: Novartis AG is far larger — about 330.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.37%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Oxford Lane Capital Corp for 49 Days on average.
| NVS | OXLC | |
|---|---|---|
Market Cap | $274.00B | $829.34M |
Volume | 1,852,137 | 1,709,917 |
Sector | Health | Financials |
52-Week High | $168.62 | $16.74 |
52-Week Low | $121.80 | $8.15 |
Typical Hold Time | 82 Days | 49 Days |
Enterprise Value | $315.32B | $1.22B |
Dividend Yield | 3.31% | 28.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook and negative profitability metrics. Recent earnings misses and a sharp decline in net income for 2026 highlight fundamental challenges, though the stock pays consistent dividends. Analyst sentiment is mixed, with a 50% buy rating but cautious media coverage on sustainability.
The outlook remains risky due to volatile earnings, high payout ratios, and NAV erosion. Potential exists for value investors attracted by the P/B discount and high yield, but significant headwinds in CLO market exposure and operational cash flow deficits warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
